Evaluation of health research: Measuring costs and socioeconomic effects

International Journal of Preventive Medicine

Volumn 2, Issue 4, 2011, Pages 203-215

  Roback, Kerstin ^a   Dalal, Koustuv ^a   Carlsson, Per ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Innovation; Medical research; Policy making; Social impact

Indexed keywords

ANALYTIC METHOD; CLINICAL DECISION MAKING; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC DEVELOPMENT; ENVIRONMENTAL IMPACT; EVALUATION RESEARCH; FUNDING; HEALTH CARE COST; HUMAN; INVESTMENT; KNOWLEDGE BASE; LONGEVITY; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; POLICY; PRODUCTIVITY; QUALITY OF LIFE; RESOURCE ALLOCATION; REVIEW; SOCIAL STATUS; SWEDEN;

EID: 80053636987     PISSN: 20087802     EISSN: 20088213     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Bunker JP, Frazier HS, Mosteller F. Improving health: measuring effects of medical care. Milbank Q 1994; 72(2): 225-58.
2. Cutler DM, McClellan M. Is technological change in medicine worth it? Health Aff (Millwood) 2001; 20(5): 11-29.
3. Lichtenberg FR. The impact of new drug launches on longevity: evidence from longitudinal, diseaselevel data from 52 countries, 1982-2001. Int J Health Care Finance Econ 2005; 5(1): 47-73.
4. Buxton M, Hanney S, Morris S, Sundmacher L, Mestre-Ferrandiz J, Garau M, et al. Medical Research: What's it worth? Estimating the economic benefits from medical research in the UK. London: UK Evaluation Forum; 2008. p. 103.
5. Wooding S, Hanney S, Buxton M, Grant J. Payback arising from research funding: evaluation of the Arthritis Research Campaign. Rheumatology (Oxford) 2005; 44(9): 1145-56.
6. Johnston SC, Rootenberg JD, Katrak S, Smith WS, Elkins JS. Effect of a US National Institutes of Health programme of clinical trials on public health and costs. Lancet 2006; 367(9519): 1319-27.
7. Drummond MF, Davies LM, Ferris FL, III. Assessing the costs and benefits of medical research: the diabetic retinopathy study. Soc Sci Med 1992; 34(9): 973-81.
8. Murphy K, Topel R. Diminishing returns? The costs and benefits of improving health. Perspect Biol Med 2003; 46(3 Suppl): S108-S128.
9. nd ed. Canberra, Australia: Australian Society for Medical Research; 2003.
10. Luce BR, Mauskopf J, Sloan FA, Ostermann J, Paramore LC. The return on investment in health care: from 1980 to 2000. Value Health 2006; 9(3): 146-56.
11. Buxton M, Hanney S, Jones T. Estimating the economic value to societies of the impact of health research: a critical review. Bull World Health Organ 2004; 82(10): 733-9.
12. Pardes H, Manton KG, Lander ES, Tolley HD, Ullian AD, Palmer H. Effects of medical research on health care and economy. Science 1999; 283(5398): 36-7.
13. Rosenberg LE. Exceptional economic returns on investments in medical research. Med J Aust 2002; 177(7): 368-71.
14. Salter AJ, Martin BR. The economic benefits of publicly funded basic research: a critical review. Research Policy 2001; 30: 509-32.
15. Hollanders H, Arundel A. Maastricht Economic and social Research and training centre on Innovation and Technology. Maastricht, The Netherlands: Global Innovation Scoreboard; 2006.
16. Paraje G, Sadana R, Karam G. Public health. Increasing international gaps in health-related publications. Science 2005; 308(5724): 959-60.
17. Hicks D, Lee SG. Regional Economic Impacts of Federal R & D by Funding Source and Performer Type. Regional Studies 1994; 28(6): 619-32.
18. Emanuel EJ, Schnipper LE, Kamin DY, Levinson J, Lichter AS. The costs of conducting clinical research. J Clin Oncol 2003; 21(22): 4145-50.
19. The National Board of Health and Welfare. Statistik över kostnader för hälso-och sjukvården 2005. Stockholm: Socialstyrelsen; 2006. [In Swedish].
20. The Swedish Association of Local Authorities and Regions (SALAR). Statistik om hälso-och sjukvård samt regional utveckling 2001, Landstingsförbundet. Stockholm: The Swedish Association of Local Authorities and Regions (SALAR); 2011. [In Swedish].
21. Läkemedelsverket RF. Miljöpåverkan från läkemedel samt kosmetiska och hygieniska produkter. Uppsala, Swedish: Medical Products Agency; 2004. [In Swedish].
22. Roback K, Gaddlin PO, Nelson N, Persson J. Adoption of medical devices: perspectives of professionals in Swedish neonatal intensive care. Technol Health Care 2007; 15(3): 157-79.
23. Burström K. Population health and inequalities in health: measurement of health-related quality of life and changes in QALYs over time in Sweden. [Thesis]. Stockholm: ReproPrint AB, 2003. [In Swedish].
24. Burström K. Försämrad hälsorelaterad livskvalitet i Stockholms län 1998 till 2002. Resultat från två befolkningsundersökningar med EQ-5D. Stockholm: Centrum för folkhälsa; 2007. [In Swedish].
25. Bilbao-Osorio B, Rodríguez-Pose A. From R&D to Innovation and Economic Growth in the EU. Growth and Change 2004; 35(4): 434-55.
26. Brecard D, Fougeyrollas A, Le Mouel P, Lemiale L, Zagame P. Macro-economic consequences of European research policy: Prospects of the Nemesis model in the year 2030. Research Policy 2006; 35(7): 910-24.
27. Goel RK, Ram R. Research and Development Expenditures and Economic Growth: A Cross-Country Study. Economic Development and Cultural Change 1994; 42(2): 403-11.
28. Howells J. Innovation and regional economic development: A matter of perspective? Research Policy 2005; 34(8): 1220-34.
29. Statistics Sweden. Sveriges framtida befolkning 2005-2050-Reviderad befolk-ningsprognos från SCB (Population projection for Sweden 2005-2050). Statistiska Medde-landen BE 18 SM 0501; 2005.
30. Eaton J, Kortum S. Engines of growth: Domestic and foreign sources of innovation. Japan and the World Economy 1997; 9(2): 235-59.
31. Siegler M, Weisfeld A, Cronin D. Is medical research cost effective? Response to Murphy and Topel. Perspect Biol Med 2003; 46(3 Suppl): S129-S137.
32. Rodgers JE, Stough WG. Underutilization of evidence-based therapies in heart failure: the pharmacist's role. Pharmacotherapy 2007; 27(4 Pt 2): 18S-28S.
33. Doll R, Hill AB. Smoking and carcinoma of the lung; preliminary report. Br Med J 1950; 2(4682): 739-48.
34. st ed. Chicago: University Of Chicago Press; 2003. p. 206-45.
35. Claxton KP, Sculpher MJ. Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics 2006; 24(11): 1055-68.
36. Henriksson M. Cost-Effectiveness and Value of Further Research of Treatment Strategies for Cardiovascular Disease. [Dissertation]. Linköping, Sweden: Department of Medicine and Health Sciences Linköping University; 2007.
37. Oostenbrink JB, Al MJ, Oppe M, Rutten-van Molken MP. Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research. Value Health 2008; 11(7): 1070-80.